ANXA6 and breast carcinoma: Tumor-derived and AnxA6-enriched EVs have also been shown to be prometastatic in mouse mammary tumor virus-polyoma middle tumor-antigen (MMTV-PyMT) and 4T1 mouse models of breast cancer [97].